Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
US12161724B2 · kind B2 · utility
0Cited by
19References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2022 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | May 4, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are multispecific antibodies for redirecting T cells to cancers, that rely on binding of one antigen interacting portion of the antibody to a tumor-associated antigen or marker, such as epidermal growth factor receptor (EGFR), while a second antigen interacting portion can bind to an effector cell antigen on a T cell, such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.